Osteoporosis in renal failure: How accurate is the diagnosis and is there any role for bisphosphonates?

International Journal of Diabetes and Metabolism

Volumn 13, Issue 2, 2005, Pages 99-102

  Saadi, Hussein ^a   Boobes, Yousef ^b   Bernieh, Bassam ^b   Abouchacra, Samra ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

Biphosphonates; Osteoporosis; Renal failure

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CINACALCET; ESTROGEN; ETIDRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; PYRIDINOLINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TETRACYCLINE; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEVER; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MYALGIA; OSTEOMALACIA; OSTEOPOROSIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

EID: 29744433497     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: 10.1159/000497579     Document Type: Article

References (54)

1. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-773.
2. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Meade, NJ; Excerpta Medica, 1998.
3. Lindberg JS, Moe SM. Osteoporosis in end-state renal disease. Semin Nephrol 1999; 19: 115-122.
4. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in hemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922-1928.
5. Hussain R, Ahmed A, Soomro AS, et al. Frequency of metabolic bone disease in hemodialysis patients. J Pak Med Assoc 1996; 46: 83-86.
6. Hercz G, Sherrard DJ, Chan W, Pei Y. Aplastic osteodystrophy: follow-up after 5 years. Nephrol 1994; 5: 851(abstr).
7. Garraway WM, Stauffer RN, Kurland LT, O'Fallon WM. Limb fractures in a defined population. I. Frequency and distribution. Mayo Clin Proc 1979; 54: 701-707.
8. Gupta A, Kallenbach LR, Divine GW. Increased risk of hip fractures in U.S. Medicare end-stage renal disease patients. J Bone Miner Res 1997; 12 [Suppl 1]: S274.
9. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in hemodialysis patients. Nephrol Dial Transplant 1999; 14:1922-1928.
10. Stein MS, Packham DK, Ebeling PR. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996; 28: 515-522.
11. Weber TJ, Darryl Quarles L. Preventing bone loss after renal transplantation with bisphosphonates: We can...but should we? Kidney Int 2000; 57: 735-737.
12. Masud T, Langley S, Wiltshire P, et al. Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis. Br Med J 1993; 307: 172-173.
13. Ritz E, Schomig M, Bommer J. Osteodystrophy in the millennium. Kidney Int 1999; 56 (Suppl 73):S94-8.
14. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18: 1159-1166.
15. Chan YL, Furlong TJ, Cornish CJ, Posen S. Dialysis Osteodystrophy: A study involving 94 patients. Medicine 1985; 64: 296-309.
16. Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron 1985; 39: 122-129.
17. Heaf JG, Joffe P, Pdenphant J, Andersen JR. Noninvasive diagnosis of uremic osteodystrophy: uses and limitations. Am J Nephrol 1987; 7: 203-211.
18. Ha SK, Park CH, Seo JK, et al. Studies on bone markers and bone mineral density in patients with chronic renal failure. Yonsei Med J 1996; 37: 350-6.
19. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodelling in uremic patients. Kidney Int 1999; 55: 2141-2156.
20. Urena P, Prieur P, Petrover M. [Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays]. Presse Med 1996; 25: 1320-5.
21. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512.
22. Fletcher S, Jones RG, Rayner HC, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419.
23. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 290.
24. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 1169-1174.
25. The Writing Group of the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 189-196.
26. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal osteoporosis. N Engl J Med 1997; 337: 1641-1647.
27. Lieberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1443.
28. Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994; 9: 69.
29. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Therapeutics 1999; 21: 1025-1044.
30. Fan S L-S, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57: 684-690.
31. Reeves HL, Francis RM, Manas DM, et al. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transplant Surg 1998; 4: 404-409.
32. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl Med 1998; 339: 292-299.
33. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211.
34. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988; 1: 143-146.
35. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
36. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
37. Harinck HIJ, Buvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacous management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Othop 1987; 217: 79-98.
38. Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3: 5-12.
39. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996; 45: 175-179.
40. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatr Nephrol 1998; 12: 778-781.
41. Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993; 27: 447-451.
42. Yap AS, Hockings GI, Fleming SJ, Khafagi FA. Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment. Clin Nephrol 1990; 34: 225-229.
43. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37:285-290.
44. Fan S L-S, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57:684-690.
45. Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998; 83: 2324-2330.
46. Rosen HN, Moses AC, Gundberg C, et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993; 77: 664-669.
47. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological response. Clin Endocrinol (Oxf) 1991; 34: 197-204.
48. Watts RA, Skingle SJ, Bhambhani MM, et al. Treatment of Paget's disease of bone with single dose intravenous pamidronate. Ann Rheum Dis 1993; 52: 616-618.
49. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10: 134-142.
50. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989; 2:1180-1182.
51. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99: 36-42.
52. Hamdy NA, Kanis JA, Beneton NC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995; 310: 358-363.
53. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004; 19: 870-876.
54. Quarles LD. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int Suppl 2005; 96: S24-28.